191 Spam-Free Article(s) Found
Sort:
Relevance
Like
Date
Filter:
7d
All
DeepLinks
Article Searches
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2227980/wall-street-analysts-see-a-75-05-upside-in-hutchmed-hcm-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2227980 Feb 19, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 26.61% Upside in Esquire Financial Holdings, Inc. (ESQ): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2227977/wall-street-analysts-see-a-26-61-upside-in-esquire-financial-holdings-inc-esq-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2227977 Feb 19, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Esquire Financial Holdings, Inc. (ESQ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What's in the Offing for Flowserve (FLS) in Q4 Earnings? https://www.zacks.com/stock/news/2227817/what-s-in-the-offing-for-flowserve-fls-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227817 Feb 19, 2024 - Flowserve's (FLS) fourth-quarter 2023 results are likely to benefit from strength in its Pump Division segment, driven by higher aftermarket and original equipment customer sales.
Healthcare dealmakers see increased M&A, valuations in 2024: KPMG https://seekingalpha.com/news/4068613-healthcare-dealmakers-see-increased-ma-valuations-in-2024-kpmg?source=feed_sector_healthcare Feb 19, 2024 - Corporate and private equity dealmakers are anticipating an uptick in healthcare and life sciences M&A activity this year, with higher valuations, according to KPMG survey.
Sealed Air (SEE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? https://www.zacks.com/stock/news/2228583/sealed-air-see-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228583 Feb 20, 2024 - Sealed Air (SEE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gold Royalty: Market Sees U-Turn, But Better With Lower Prices https://seekingalpha.com/article/4672250-gold-royalty-market-sees-u-turn-but-better-with-lower-prices?source=feed_all_articles Feb 21, 2024 - Gold Royalty is poised to gain from the upcoming gold price surge in 2024, with promising financial improvements hinting at profitable growth ahead. See more here.
Wall Street Analysts See a 25.37% Upside in Atmus Filtration (ATMU): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2230213/wall-street-analysts-see-a-25-37-upside-in-atmus-filtration-atmu-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230213 Feb 22, 2024 - The consensus price target hints at a 25.4% upside potential for Atmus Filtration (ATMU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2230995/wall-street-analysts-see-an-185-54-upside-in-intellia-therapeutics-inc-ntla-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230995 Feb 23, 2024 - The consensus price target hints at an 185.5% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See Snowflake Inc. (SNOW) as a Buy: Should You Invest? https://www.zacks.com/stock/news/2230882/wall-street-analysts-see-snowflake-inc-snow-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2230882 Feb 23, 2024 - The average brokerage recommendation (ABR) for Snowflake Inc. (SNOW) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? https://www.zacks.com/stock/news/2230991/wall-street-analysts-see-a-70-57-upside-in-replimune-group-inc-repl-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2230991 Feb 23, 2024 - The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pages: 1234567...20

<Page 2>